These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 33271787)

  • 1. Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance.
    Bush NG; Diez-Santos I; Abbott LR; Maxwell A
    Molecules; 2020 Dec; 25(23):. PubMed ID: 33271787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of quinolone action and resistance.
    Aldred KJ; Kerns RJ; Osheroff N
    Biochemistry; 2014 Mar; 53(10):1565-74. PubMed ID: 24576155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA gyrase, topoisomerase IV, and the 4-quinolones.
    Drlica K; Zhao X
    Microbiol Mol Biol Rev; 1997 Sep; 61(3):377-92. PubMed ID: 9293187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanism of action of quinolones].
    Smith JT
    Infection; 1986; 14 Suppl 1():S3-15. PubMed ID: 2420724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis for the differential quinolone susceptibility of mycobacterial DNA gyrase.
    Kumar R; Madhumathi BS; Nagaraja V
    Antimicrob Agents Chemother; 2014; 58(4):2013-20. PubMed ID: 24419347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with
    Morgan H; Lipka-Lloyd M; Warren AJ; Hughes N; Holmes J; Burton NP; Mahenthiralingam E; Bax BD
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of quinolone action and resistance: where do we stand?
    Correia S; Poeta P; Hébraud M; Capelo JL; Igrejas G
    J Med Microbiol; 2017 May; 66(5):551-559. PubMed ID: 28504927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial action of quinolones: from target to network.
    Cheng G; Hao H; Dai M; Liu Z; Yuan Z
    Eur J Med Chem; 2013 Aug; 66():555-62. PubMed ID: 23528390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.
    Aldred KJ; Schwanz HA; Li G; McPherson SA; Turnbough CL; Kerns RJ; Osheroff N
    ACS Chem Biol; 2013 Dec; 8(12):2660-8. PubMed ID: 24047414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Campylobacter jejuni DNA gyrase as the target of quinolones.
    Changkwanyeun R; Usui M; Kongsoi S; Yokoyama K; Kim H; Suthienkul O; Changkaew K; Nakajima C; Tamura Y; Suzuki Y
    J Infect Chemother; 2015 Aug; 21(8):604-9. PubMed ID: 26096494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of action of and resistance to quinolones.
    Fàbrega A; Madurga S; Giralt E; Vila J
    Microb Biotechnol; 2009 Jan; 2(1):40-61. PubMed ID: 21261881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topoisomerase IV is a target of quinolones in Escherichia coli.
    Khodursky AB; Zechiedrich EL; Cozzarelli NR
    Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11801-5. PubMed ID: 8524852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance.
    Hooper DC
    Clin Infect Dis; 1998 Aug; 27 Suppl 1():S54-63. PubMed ID: 9710672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of drug resistance: quinolone resistance.
    Hooper DC; Jacoby GA
    Ann N Y Acad Sci; 2015 Sep; 1354(1):12-31. PubMed ID: 26190223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of mutational patterns in quinolone resistance-determining regions of GyrA and ParC of clinical isolates.
    Ostrer L; Khodursky RF; Johnson JR; Hiasa H; Khodursky A
    Int J Antimicrob Agents; 2019 Mar; 53(3):318-324. PubMed ID: 30582984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II.
    Gruger T; Nitiss JL; Maxwell A; Zechiedrich EL; Heisig P; Seeber S; Pommier Y; Strumberg D
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4495-504. PubMed ID: 15561817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The molecular physiological and genetic mechanisms underlying the superb efficacy of quinolones].
    Long QX; He Y; Xie JP
    Yao Xue Xue Bao; 2012 Aug; 47(8):969-77. PubMed ID: 23162891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quinolone resistance in bacteria: emphasis on plasmid-mediated mechanisms.
    Li XZ
    Int J Antimicrob Agents; 2005 Jun; 25(6):453-63. PubMed ID: 15890498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity.
    Naeem A; Badshah SL; Muska M; Ahmad N; Khan K
    Molecules; 2016 Mar; 21(4):268. PubMed ID: 27043501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.